Loading...
OTCM
OTLC
, Last price  
USD
Name

Oncotelic Therapeutics Inc

Chart & performance

D1W1MN
OTCM:OTLC chart
P/E
—
P/S
—
EPS
0.55
Vol. 1Y
—
Shs. 5Y
36.81%
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
012,00012,000000156,00095,00095,00000-100-10001,740,8550070,00000
Net income
249m
P
-15,457,000-20,389,000-21,401,000-24,728,000-23,770,000-9,653,000-8,079,000-8,277,000-12,647,000-13,654,000-13,654,000-13,812,000-2,737,000-7,387,615-11,500,923-11,393,85517,819,719-7,903,093-4,523,932,000249,279,832
CFO
-1m
L+86.84%
-13,303,000-17,184,000-23,398,000-28,669,000-20,427,000-11,784,000-8,335,000-7,001,000-12,151,000-11,927,000-15,238,000-10,932,000-2,844,000-2,280,690-2,812,000-4,434,465-1,452,562-1,321,047-740,267-1,383,145

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.

Key people

Vuong Trieu
Chief Executive Officer · since 2019
Chulho Park
Chief Technology Officer · since 2019
Barbara Riching
Chief Financial Officer, Vice President · since 2013
URL
https://www.oncotelic.com/
IPO date
Aug 26, 1993
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT